What are Regeneron Pharmaceuticals's profit margins?

Regeneron Pharmaceuticals (REGN) runs a 93.9% gross margin and a 24.3% operating margin, with a 29.6% net margin.

Where do Regeneron Pharmaceuticals's ratios come from?

Every ratio is computed from Regeneron Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.

Regeneron Pharmaceuticals REGN Ratios & Valuation

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Profitability
Operating margin	24.3%-2.9pp	24.9%-3.2pp	25.9%-2.8pp	27%-1.9pp	27.2%-2.2pp
Net margin	29.6%-2.3pp	31.4%+0.3pp	32.1%-1.5pp	31.4%-0.7pp	31.9%+2.5pp
EBITDA margin	27.9%-2.8pp	28.7%-2.8pp	29.6%-2.5pp	30.6%-1.7pp	30.7%-2.0pp
Free cash flow margin	27.6%+5.5pp	28.4%+2.6pp	29.6%+4.8pp	27.1%+2.4pp	22%-9.0pp
Returns
Return on equity	14.5%-1.4pp	14.9%-1.1pp	15.2%-2.0pp	15.3%-1.2pp	16%+0.7pp
Return on assets	11.3%-1.2pp	11.5%-1.0pp	11.8%-1.6pp	12%-0.9pp	12.5%+0.5pp
Return on invested capital	10.3%-2.0pp	10.1%-3.1pp	10.7%-2.7pp	11.8%-1.9pp	12.3%-2.5pp
Efficiency
Asset turnover	0.4×0.0×	0.4×0.0×	0.4×0.0×	0.4×0.0×	0.4×0.0×
Liquidity
Current ratio	3.6×-1.4×	4.1×-0.6×	4.1×-1.2×	4.6×-0.8×	4.9×-0.3×
Quick ratio	3×-1.1×	3.4×-0.6×	3.3×-1.1×	3.7×-0.9×	4×-0.5×
Cash ratio	0.6×-0.3×	0.7×+0.1×	0.6×0.0×	0.5×0.0×	0.9×+0.1×
Leverage
Debt-to-equity	0.1×0.0×	0.1×0.0×	0.1×0.0×	0.1×0.0×	0.1×0.0×
Debt-to-assets	0.1×0.0×	0.1×0.0×	0.1×0.0×	0.1×0.0×	0.1×0.0×
Net debt / EBITDA	-0.1×0.0×	-0×-0.1×	0×-0.1×	0.2×0.0×	-0.1×-0.1×
Interest coverage	75.6×-4.5×	81.7×+9.4×	87.6×+24.5×	104.9×+46.7×	80.1×+26.0×
Per Share
Book value per share	$291.77+10.4%	$287.82+12.9%	$288.79+14.4%	$275.68+12.8%	$264.28+12.7%
Valuation
Market capitalization	$81.68B+17.8%	$81.12B+3.6%	$59.59B-47.6%	$56.39B-50.2%	$69.34B-33.2%
Enterprise value	$81.42B+18.1%	$80.97B+2.9%	$59.79B-47.7%	$57.08B-50.0%	$68.95B-33.6%
Price / earnings	18.5×+3.1×	18×+0.3×	13×-11.4×	12.6×-13.6×	15.4×-11.5×
Price / sales	5.5×+0.6×	5.7×+0.1×	4.2×-4.0×	4×-4.4×	4.9×-3.0×
Price / book	2.6×+0.2×	2.6×-0.1×	1.9×-2.0×	1.9×-2.1×	2.4×-1.5×
EV / EBITDA	19.5×+3.6×	19.6×+2.0×	14.2×-11.5×	13.1×-13.1×	15.9×-8.3×
EV / sales	5.5×+0.6×	5.6×+0.1×	4.2×-4.1×	4×-4.4×	4.9×-3.0×
Free cash flow yield	5%+0.6pp	5%+0.3pp	7.1%+4.1pp	6.8%+3.9pp	4.5%+0.6pp
Earnings yield	5.4%-1.1pp	5.6%-0.1pp	7.7%+3.6pp	7.9%+4.1pp	6.5%+2.8pp
Dividend yield	0.5%+0.3pp	0.5%—	0.5%—	0.3%—	0.1%—

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Regeneron Pharmaceuticals.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Regeneron Pharmaceuticals's profit margins?: Regeneron Pharmaceuticals (REGN) runs a 93.9% gross margin and a 24.3% operating margin, with a 29.6% net margin.
Where do Regeneron Pharmaceuticals's ratios come from?: Every ratio is computed from Regeneron Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.